{"id":30997,"date":"2025-02-11T16:45:55","date_gmt":"2025-02-11T11:15:55","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30997"},"modified":"2025-02-11T16:45:57","modified_gmt":"2025-02-11T11:15:57","slug":"pharma-news-for-biodexa-abbvie-insmed","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed","title":{"rendered":"Immix Bio\u2019s NXC-201 Gets FDA RMAT for AL Amyloidosis; Biodexa\u2019s eRapa Wins Fast Track for Familial Adenomatous Polyposis; AbbVie\u2019s EMBLAVEO Approved for Complicated Intra-Abdominal Infections; Insmed\u2019s Brensocatib Gains Priority Review for Bronchiectasis; Aro Bio\u2019s ABX1100 IND Cleared for Pompe Disease"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a00e732e4521\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a00e732e4521\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed\/#Immix_Biopharmas_NXC-201_Receives_FDA_RMAT_Designation_for_RelapsedRefractory_AL_Amyloidosis\" >Immix Biopharma&#8217;s NXC-201 Receives FDA RMAT Designation for Relapsed\/Refractory AL Amyloidosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed\/#Biodexas_eRapa_Granted_FDA_Fast_Track_for_Familial_Adenomatous_Polyposis\" >Biodexa&#8217;s eRapa Granted FDA Fast Track for Familial Adenomatous Polyposis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed\/#FDA_Approves_AbbVies_EMBLAVEO_for_Complicated_Intra-Abdominal_Infections\" >FDA Approves AbbVie\u2019s EMBLAVEO for Complicated Intra-Abdominal Infections<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed\/#Insmeds_Brensocatib_Gets_FDA_Priority_Review_for_Bronchiectasis_Treatment\" >Insmed\u2019s Brensocatib Gets FDA Priority Review for Bronchiectasis Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed\/#Aro_Biotherapeutics_Secures_FDA_IND_Clearance_for_ABX1100_in_Late-Onset_Pompe_Disease\" >Aro Biotherapeutics Secures FDA IND Clearance for ABX1100 in Late-Onset Pompe Disease<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-immix-biopharma-s-nxc-201-receives-fda-rmat-designation-for-relapsed-refractory-al-amyloidosis\"><span class=\"ez-toc-section\" id=\"Immix_Biopharmas_NXC-201_Receives_FDA_RMAT_Designation_for_RelapsedRefractory_AL_Amyloidosis\"><\/span>Immix Biopharma&#8217;s NXC-201 Receives FDA RMAT Designation for Relapsed\/Refractory AL Amyloidosis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Immix Biopharma<\/strong> has received the FDA\u2019s <strong>RMAT (Regenerative Medicine Advanced Therapy) designation <\/strong>for <strong>NXC-201,<\/strong> a sterically optimized <a href=\"https:\/\/www.delveinsight.com\/report-store\/chimeric-antigen-receptor-car-t-cell-therapy-market\"><strong>CAR-T therapy<\/strong><\/a> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/al-amyloidosis-market\"><strong>relapsed\/refractory AL amyloidosis<\/strong><\/a><strong>. <\/strong>The designation is granted to regenerative medicines targeting serious conditions with the potential to treat, modify, reverse, or cure disease, and is designed to accelerate their development and regulatory review. AL amyloidosis currently lacks FDA-approved therapies, making this designation a significant step in advancing potential treatment options for patients facing limited alternatives.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;Receiving FDA RMAT designation underscores the strength of our NXC-201 data and highlights its potential to provide a much-needed treatment option for patients with relapsed\/refractory AL amyloidosis,&#8221; said <\/em><strong><em>Ilya Rachman, MD, PhD, Chief Executive Officer of Immix Biopharma.<\/em><\/strong><em> Gabriel Morris, the company\u2019s Chief Financial Officer, added, &#8220;Following the successful completion of the safety run-in segment, enrollment in NEXICART-2 has accelerated. We are eager to provide further updates on our progress, including developments in the NEXICART-2 trial, in the first half of 2025.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>RMAT designation offers several advantages, including early and frequent interactions with the FDA, guidance on surrogate or intermediate endpoints, and streamlined post-approval requirements, potentially expediting NXC-201\u2019s path to market approval. As Immix Biopharma advances its clinical trials, this milestone strengthens its position in the development of cell therapies for AL amyloidosis and other immune-mediated diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-biodexa-s-erapa-granted-fda-fast-track-for-familial-adenomatous-polyposis\"><span class=\"ez-toc-section\" id=\"Biodexas_eRapa_Granted_FDA_Fast_Track_for_Familial_Adenomatous_Polyposis\"><\/span>Biodexa&#8217;s eRapa Granted FDA Fast Track for Familial Adenomatous Polyposis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Biodexa Pharmaceuticals<\/strong> announced that the <strong>FDA<\/strong> has granted<strong> Fast Track designation for eRapa, <\/strong>an encapsulated form of rapamycin being developed for <a href=\"https:\/\/www.delveinsight.com\/report-store\/familial-adenomatous-polyposis-market\"><strong>familial<\/strong> <strong>adenomatous polyposis<\/strong><\/a><strong>.<\/strong> This designation is intended to accelerate the development and review of therapies for serious conditions with unmet medical needs. FAP is a hereditary disorder characterized by the growth of numerous polyps in the colon and rectum, which, if left untreated, inevitably leads to colorectal cancer. Currently, the only treatment option is surgical resection, highlighting the urgent need for alternative therapies.<\/p>\n\n\n\n<p>In a Phase II study, eRapa demonstrated a promising safety profile and efficacy, with a median 17% reduction in total polyp burden at 12 months and an overall 75% non-progression rate. Patients in the preferred dosing cohort experienced an 89% non-progression rate and a 29% median reduction in polyp burden. These findings support eRapa\u2019s potential as a non-surgical treatment option for FAP, paving the way for its registrational Phase III study.<\/p>\n\n\n\n<p>Biodexa has already secured FDA Orphan Drug designation for eRapa in FAP and plans to seek similar recognition in Europe. With no approved medical treatments available, eRapa could represent a breakthrough for patients at risk of developing colorectal cancer. The company remains focused on advancing its clinical program to bring much-needed therapy to individuals affected by this rare but life-threatening condition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-abbvie-s-emblaveo-for-complicated-intra-abdominal-infections\"><span class=\"ez-toc-section\" id=\"FDA_Approves_AbbVies_EMBLAVEO_for_Complicated_Intra-Abdominal_Infections\"><\/span>FDA Approves AbbVie\u2019s EMBLAVEO for Complicated Intra-Abdominal Infections<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AbbVie<\/strong> has received FDA approval for <strong>EMBLAVEO,<\/strong> the first fixed-dose <strong>intravenous monobactam\/\u03b2-lactamase inhibitor<\/strong> combination antibiotic. Approved for use with metronidazole in adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/complicated-intra-abdominal-infections-market\"><strong>complicated intra-abdominal infections (cIAI)<\/strong><\/a><strong>,<\/strong> it targets multidrug-resistant Gram-negative bacteria, a growing global health concern due to rising<strong> antimicrobial resistance (AMR)<\/strong>. The approval is based on limited clinical safety and efficacy data, addressing a critical gap in available treatment options.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;The evolution of antimicrobial resistance has left many patients with few or no treatment options, leading to extended hospital stays and increased mortality,&#8221; said <\/em><strong><em>Dr. James A. McKinnell, an infectious disease specialist. <\/em><\/strong><em>&#8220;EMBLAVEO offers physicians a crucial new option to combat these challenging infections.&#8221; <\/em><strong><em>Dr. Roopal Thakkar, AbbVie\u2019s Chief Scientific Officer, <\/em><\/strong><em>added, &#8220;As bacteria evolve, collaboration across industry, government, and clinical experts is essential. We are proud to bring this novel treatment to the fight against AMR.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>EMBLAVEO combines aztreonam, a monobactam antibiotic, with avibactam, a \u03b2-lactamase inhibitor that protects against resistant bacterial enzymes, restoring its efficacy against highly resistant pathogens. Supported by prior studies and the Phase III REVISIT trial, the drug received FDA Fast Track and QIDP designations, expediting its development and regulatory review. Its approval marks a significant advancement in the treatment of severe, drug-resistant infections.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-insmed-s-brensocatib-gets-fda-priority-review-for-bronchiectasis-treatment\"><span class=\"ez-toc-section\" id=\"Insmeds_Brensocatib_Gets_FDA_Priority_Review_for_Bronchiectasis_Treatment\"><\/span>Insmed\u2019s Brensocatib Gets FDA Priority Review for Bronchiectasis Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Insmed<\/strong> has announced that the <strong>FDA <\/strong>has accepted its <strong>New Drug Application (NDA)<\/strong> for<strong> brensocatib, <\/strong>granting it a Priority Review for<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market\"><strong>non-cystic fibrosis bronchiectasis<\/strong><\/a><strong>. <\/strong>With a target action date of August 12, 2025, brensocatib could become the first approved treatment for the disease and the first in a new class of DPP1 inhibitors targeting neutrophil-mediated conditions. The decision follows strong results from the Phase III ASPEN study, which demonstrated significant reductions in pulmonary exacerbations over a 52-week period.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;Bronchiectasis is a chronic disease with no approved treatments, leaving many patients without options to manage pulmonary exacerbations,&#8221; said <\/em><strong><em>Martina Flammer,<\/em><\/strong><em> <\/em><strong><em>M.D., MBA, Chief Medical Officer of Insmed.<\/em><\/strong><em> &#8220;Brensocatib has the potential to transform the treatment landscape, and we look forward to working with the FDA to bring this much-needed therapy to patients as soon as possible.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA had previously granted brensocatib Breakthrough Therapy Designation, recognizing its potential to offer significant improvements over existing treatments. The drug was well-tolerated in clinical trials, with common adverse events including mild respiratory infections and headaches. If approved, brensocatib would represent a major step forward in addressing a condition that currently lacks targeted therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-aro-biotherapeutics-secures-fda-ind-clearance-for-abx1100-in-late-onset-pompe-disease\"><span class=\"ez-toc-section\" id=\"Aro_Biotherapeutics_Secures_FDA_IND_Clearance_for_ABX1100_in_Late-Onset_Pompe_Disease\"><\/span>Aro Biotherapeutics Secures FDA IND Clearance for ABX1100 in Late-Onset Pompe Disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Aro Biotherapeutics<\/strong> announced that the FDA has cleared its <strong>Investigational New Drug (IND) application <\/strong>for <strong>ABX1100<\/strong>, a novel siRNA therapy designed for<strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-market\" class=\"ek-link\">late-onset Pompe disease (LOPD)<\/a><\/strong>. The company is advancing the treatment in a Phase I trial and plans to present encouraging early data at the 2025 WORLDSymposium. In a completed Phase I study in healthy volunteers, ABX1100 demonstrated durable knockdown of glycogen synthase 1 (GYS1) mRNA and protein in muscle tissue, supporting its potential as a targeted therapy for LOPD.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cFDA clearance of our IND application, combined with the promising data from our Phase I healthy volunteer study, provides tremendous momentum for the ABX1100 clinical development program,\u201d said <\/em><strong><em>Susan Dillon, Ph.D., co-founder, president, and CEO of Aro Biotherapeutics. <\/em><\/strong><em>\u201cAttaining these milestones bolsters our confidence as we continue enrolling patients with LOPD in our ongoing Phase I trial.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>LOPD is caused by a genetic deficiency that leads to excessive glycogen buildup in muscle tissue, resulting in progressive weakness. Using Aro\u2019s Centyrin technology, ABX1100 delivers an siRNA payload directly to muscle cells to inhibit GYS1, reducing glycogen production. The completed Phase I study in healthy volunteers showed dose-dependent and sustained reductions of GYS1, with a 70% knockdown observed 10 weeks after two doses.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>ABX1100 was well-tolerated, with no serious adverse events reported. \u201cThese results demonstrate consistent and dose-dependent delivery to muscle, translating our Centyrin-siRNA platform from the bench to bedside,\u201d said<\/em><strong><em> Karyn O\u2019Neil, Ph.D., co-founder and chief scientific officer of Aro.<\/em><\/strong><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Immix Biopharma&#8217;s NXC-201 Receives FDA RMAT Designation for Relapsed\/Refractory AL Amyloidosis Immix Biopharma has received the FDA\u2019s RMAT (Regenerative Medicine Advanced Therapy) designation for NXC-201, a sterically optimized CAR-T therapy for relapsed\/refractory AL amyloidosis. The designation is granted to regenerative medicines targeting serious conditions with the potential to treat, modify, reverse, or cure disease, and [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30998,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17014,1257,204,777,17448,704,349,420,18004,639,489,5789],"industry":[17225],"therapeutic_areas":[17240,17239,17238,17243],"class_list":["post-30997","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-al-amyloidosis","tag-car-t-therapy","tag-delveinsight","tag-familial-adenomatous-polyposis","tag-familial-adenomatous-polyposis-market","tag-fda","tag-latest-pharma-news","tag-news","tag-non-cystic-fibrosis-bronchiectasis","tag-pharma-news","tag-pompe-disease","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-gastroenterology","therapeutic_areas-genetic-disorders","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Biodexa, AbbVie, Insmed<\/title>\n<meta name=\"description\" content=\"Immix Bio\u2019s NXC-201, Biodexa\u2019s eRapa, AbbVie\u2019s EMBLAVEO, Insmed\u2019s Brensocatib, Aro Bio\u2019s ABX1100\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Biodexa, AbbVie, Insmed\" \/>\n<meta property=\"og:description\" content=\"Immix Bio\u2019s NXC-201, Biodexa\u2019s eRapa, AbbVie\u2019s EMBLAVEO, Insmed\u2019s Brensocatib, Aro Bio\u2019s ABX1100\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-11T11:15:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-11T11:15:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/11164527\/pharma-news-for-biodexa-abbvie-insmed.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Biodexa, AbbVie, Insmed","description":"Immix Bio\u2019s NXC-201, Biodexa\u2019s eRapa, AbbVie\u2019s EMBLAVEO, Insmed\u2019s Brensocatib, Aro Bio\u2019s ABX1100","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Biodexa, AbbVie, Insmed","og_description":"Immix Bio\u2019s NXC-201, Biodexa\u2019s eRapa, AbbVie\u2019s EMBLAVEO, Insmed\u2019s Brensocatib, Aro Bio\u2019s ABX1100","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-11T11:15:55+00:00","article_modified_time":"2025-02-11T11:15:57+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/11164527\/pharma-news-for-biodexa-abbvie-insmed.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed","name":"Pharma News | Biodexa, AbbVie, Insmed","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/11164527\/pharma-news-for-biodexa-abbvie-insmed.png","datePublished":"2025-02-11T11:15:55+00:00","dateModified":"2025-02-11T11:15:57+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Immix Bio\u2019s NXC-201, Biodexa\u2019s eRapa, AbbVie\u2019s EMBLAVEO, Insmed\u2019s Brensocatib, Aro Bio\u2019s ABX1100","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-biodexa-abbvie-insmed#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/11164527\/pharma-news-for-biodexa-abbvie-insmed.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/11164527\/pharma-news-for-biodexa-abbvie-insmed.png","width":772,"height":482,"caption":"pharma-news-for-biodexa-abbvie-insmed"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/11164527\/pharma-news-for-biodexa-abbvie-insmed-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AL Amyloidosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAR-T therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Familial Adenomatous Polyposis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Familial Adenomatous Polyposis Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Cystic Fibrosis Bronchiectasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pompe Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AL Amyloidosis<\/span>","<span class=\"advgb-post-tax-term\">CAR-T therapy<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Familial Adenomatous Polyposis<\/span>","<span class=\"advgb-post-tax-term\">Familial Adenomatous Polyposis Market<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-Cystic Fibrosis Bronchiectasis<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Pompe Disease<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Feb 11, 2025","modified":"Updated on Feb 11, 2025"},"absolute_dates_time":{"created":"Posted on Feb 11, 2025 4:45 pm","modified":"Updated on Feb 11, 2025 4:45 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30997"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30997\/revisions"}],"predecessor-version":[{"id":30999,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30997\/revisions\/30999"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30998"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30997"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30997"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}